Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study
创建时间：
2019-01-09
